Published in J Surg Res on November 01, 2003
Inhibition of interleukin-1β decreases aneurysm formation and progression in a novel model of thoracic aortic aneurysms. Circulation (2014) 2.28
Elastin degradation and calcification in an abdominal aorta injury model: role of matrix metalloproteinases. Circulation (2004) 1.65
Pharmacologically induced thoracic and abdominal aortic aneurysms in mice. Hypertension (2010) 1.37
Spatiotemporal expression and localization of matrix metalloproteinas-9 in a murine model of thoracic aortic aneurysm. J Vasc Surg (2006) 1.01
Alterations in aortic cellular constituents during thoracic aortic aneurysm development: myofibroblast-mediated vascular remodeling. Am J Pathol (2009) 0.98
Thoracic aortic disease in tuberous sclerosis complex: molecular pathogenesis and potential therapies in Tsc2+/- mice. Hum Mol Genet (2010) 0.96
Altered transforming growth factor-beta signaling in a murine model of thoracic aortic aneurysm. J Vasc Res (2008) 0.95
Alterations in membrane type-1 matrix metalloproteinase abundance after the induction of thoracic aortic aneurysm in a murine model. Am J Physiol Heart Circ Physiol (2010) 0.86
Cellular phenotype transformation occurs during thoracic aortic aneurysm development. J Thorac Cardiovasc Surg (2010) 0.86
Reproducible porcine model of thoracic aortic aneurysm. Circulation (2013) 0.78
The decellularized vascular allograft as an experimental platform for developing a biocompatible small-diameter graft conduit in a rat surgical model. Yonsei Med J (2011) 0.77
Carotid calcification in mice: a new model to study the effects of arterial stiffness on the brain. J Am Heart Assoc (2013) 0.76
MMP-2 Isoforms in Aortic Tissue and Serum of Patients with Ascending Aortic Aneurysms and Aortic Root Aneurysms. PLoS One (2016) 0.75
N-(2-Aminoethyl) Ethanolamine-Induced Morphological, Biochemical, and Biophysical Alterations in Vascular Matrix Associated With Dissecting Aortic Aneurysm. Toxicol Sci (2015) 0.75
Lessons from Animal Models of Arterial Aneurysm. Aorta (Stamford) (2013) 0.75
Aortic Aneurysms. Arterioscler Thromb Vasc Biol (2017) 0.75
Large animal models of heart failure: a critical link in the translation of basic science to clinical practice. Circ Heart Fail (2009) 2.72
Animal models of heart failure: a scientific statement from the American Heart Association. Circ Res (2012) 2.31
Matrix metalloproteinase-9 gene deletion facilitates angiogenesis after myocardial infarction. Am J Physiol Heart Circ Physiol (2005) 2.23
Cardiac support device modifies left ventricular geometry and myocardial structure after myocardial infarction. Circulation (2005) 2.14
Region- and type-specific induction of matrix metalloproteinases in post-myocardial infarction remodeling. Circulation (2003) 1.95
Myocardial infarct expansion and matrix metalloproteinase inhibition. Circulation (2003) 1.91
Aortic dilatation with bicuspid aortic valves: cusp fusion correlates to matrix metalloproteinases and inhibitors. Ann Thorac Surg (2011) 1.88
Noninvasive targeted imaging of matrix metalloproteinase activation in a murine model of postinfarction remodeling. Circulation (2005) 1.82
Targeted myocardial microinjections of a biocomposite material reduces infarct expansion in pigs. Ann Thorac Surg (2008) 1.82
Preoperative statin treatment is associated with reduced postoperative mortality and morbidity in patients undergoing cardiac surgery: an 8-year retrospective cohort study. J Thorac Cardiovasc Surg (2006) 1.78
Mitral regurgitation augments post-myocardial infarction remodeling failure of hypertrophic compensation. J Am Coll Cardiol (2008) 1.70
Specific temporal profile of matrix metalloproteinase release occurs in patients after myocardial infarction: relation to left ventricular remodeling. Circulation (2006) 1.69
Age-dependent changes in myocardial matrix metalloproteinase/tissue inhibitor of metalloproteinase profiles and fibroblast function. Cardiovasc Res (2004) 1.68
Angiotensin II receptor blockade does not improve left ventricular function and remodeling in subacute mitral regurgitation in the dog. J Am Coll Cardiol (2002) 1.65
Cardioprotective and antiapoptotic effects of heme oxygenase-1 in the failing heart. Circulation (2010) 1.64
Aprotinin in cardiac surgery: a review of conventional and novel mechanisms of action. Anesth Analg (2007) 1.57
Plasma biomarkers for distinguishing etiologic subtypes of thoracic aortic aneurysm disease. J Thorac Cardiovasc Surg (2013) 1.54
Functional and morphological evidence for a ventricular conduction system in zebrafish and Xenopus hearts. Am J Physiol Heart Circ Physiol (2003) 1.54
Standardized preoperative corticosteroid treatment in neonates undergoing cardiac surgery: results from a randomized trial. J Thorac Cardiovasc Surg (2011) 1.50
Accelerated LV remodeling after myocardial infarction in TIMP-1-deficient mice: effects of exogenous MMP inhibition. Am J Physiol Heart Circ Physiol (2005) 1.47
Matrix metalloproteinase-7 affects connexin-43 levels, electrical conduction, and survival after myocardial infarction. Circulation (2006) 1.46
A prospective, randomized study of endothelin and postoperative recovery in off-pump versus conventional coronary artery bypass surgery. J Cardiothorac Vasc Anesth (2004) 1.46
Deficiency of TIMP-1 exacerbates LV remodeling after myocardial infarction in mice. Am J Physiol Heart Circ Physiol (2002) 1.45
Selective spatiotemporal induction of matrix metalloproteinase-2 and matrix metalloproteinase-9 transcription after myocardial infarction. Am J Physiol Heart Circ Physiol (2006) 1.43
Expression of matrix metalloproteinases and endogenous inhibitors within ascending aortic aneurysms of patients with bicuspid or tricuspid aortic valves. J Thorac Cardiovasc Surg (2007) 1.42
Transforming growth factor-beta signaling in thoracic aortic aneurysm development: a paradox in pathogenesis. J Vasc Res (2008) 1.42
Matrix metalloproteinase abundance in human myocardial fibroblasts: effects of sustained pharmacologic matrix metalloproteinase inhibition. J Mol Cell Cardiol (2003) 1.42
Extracellular matrix remodeling following myocardial injury. Ann Med (2003) 1.41
Selective targeting and timing of matrix metalloproteinase inhibition in post-myocardial infarction remodeling. Circulation (2003) 1.40
Modulation of calcium transport improves myocardial contractility and enzyme profiles after prolonged ischemia-reperfusion. Ann Thorac Surg (2003) 1.39
Hemodynamics is a key epigenetic factor in development of the cardiac conduction system. Circ Res (2003) 1.35
Expression of matrix metalloproteinases and endogenous inhibitors within ascending aortic aneurysms of patients with Marfan syndrome. Circulation (2006) 1.32
Proteinase systems and thoracic aortic aneurysm progression. J Surg Res (2007) 1.32
Pathways of matrix metalloproteinase induction in heart failure: bioactive molecules and transcriptional regulation. Cardiovasc Res (2006) 1.29
High-frequency ultrasonographic imaging of avian cardiovascular development. Dev Dyn (2007) 1.29
Fibulin-1 is required for morphogenesis of neural crest-derived structures. Dev Biol (2008) 1.26
Targeted insertion of the Cre-recombinase gene at the phenylethanolamine n-methyltransferase locus: a new model for studying the developmental distribution of adrenergic cells. Dev Dyn (2004) 1.25
Early postoperative outcomes and blood product utilization in adult cardiac surgery: the post-aprotinin era. Circulation (2011) 1.24
Versican proteolysis mediates myocardial regression during outflow tract development. Dev Dyn (2007) 1.24
Mesenchymal cell transplantation and myocardial remodeling after myocardial infarction. Circulation (2009) 1.23
Regional heterogeneity within the aorta: relevance to aneurysm disease. J Thorac Cardiovasc Surg (2008) 1.23
Tumor necrosis factor-alpha and myocardial remodeling in progression of heart failure: a current perspective. Cardiovasc Res (2002) 1.21
Cellular mechanisms of tissue fibrosis. 2. Contributory pathways leading to myocardial fibrosis: moving beyond collagen expression. Am J Physiol Cell Physiol (2012) 1.21
Selective microRNA suppression in human thoracic aneurysms: relationship of miR-29a to aortic size and proteolytic induction. Circ Cardiovasc Genet (2011) 1.20
Early repair of moderate ischemic mitral regurgitation reverses left ventricular remodeling: a functional and molecular study. Circulation (2007) 1.20
Myosin light chain phosphorylation is critical for adaptation to cardiac stress. Circulation (2012) 1.19
Plasma biomarkers that reflect determinants of matrix composition identify the presence of left ventricular hypertrophy and diastolic heart failure. Circ Heart Fail (2011) 1.19
TNF-alpha and myocardial matrix metalloproteinases in heart failure: relationship to LV remodeling. Am J Physiol Heart Circ Physiol (2002) 1.17
Spatiotemporal pattern of commitment to slowed proliferation in the embryonic mouse heart indicates progressive differentiation of the cardiac conduction system. Anat Rec A Discov Mol Cell Evol Biol (2003) 1.17
Left ventricular form and function: scientific priorities and strategic planning for development of new views of disease. Circulation (2004) 1.16
Effects of age on plasma matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases (TIMPs). J Card Fail (2007) 1.16
Effects of deletion of the matrix metalloproteinase 9 gene on development of murine thoracic aortic aneurysms. Circulation (2005) 1.15
Changes in extracellular collagen matrix alter myocardial systolic performance. Am J Physiol Heart Circ Physiol (2003) 1.15
Matrix metalloproteinase inhibition modifies left ventricular remodeling after myocardial infarction in pigs. J Thorac Cardiovasc Surg (2003) 1.13
Trafficking of the membrane type-1 matrix metalloproteinase in ischemia and reperfusion: relation to interstitial membrane type-1 matrix metalloproteinase activity. Circulation (2005) 1.11
Cellular changes in experimental left heart hypoplasia. Anat Rec (2002) 1.10
Cardiac restricted overexpression of membrane type-1 matrix metalloproteinase causes adverse myocardial remodeling following myocardial infarction. J Biol Chem (2010) 1.09
Local hydrogel release of recombinant TIMP-3 attenuates adverse left ventricular remodeling after experimental myocardial infarction. Sci Transl Med (2014) 1.08
Alterations in cultured myocardial fibroblast function following the development of left ventricular failure. J Mol Cell Cardiol (2006) 1.08
Analyzing Propensity Matched Zero-Inflated Count Outcomes in Observational Studies. J Appl Stat (2014) 1.07
Myocyte proliferation in the developing heart. Dev Dyn (2011) 1.07
Relationship between the temporal profile of plasma microRNA and left ventricular remodeling in patients after myocardial infarction. Circ Cardiovasc Genet (2011) 1.06
Infarct size reduction and attenuation of global left ventricular remodeling with the CorCap cardiac support device following acute myocardial infarction in sheep. Heart Fail Rev (2005) 1.06
Progressive induction of left ventricular pressure overload in a large animal model elicits myocardial remodeling and a unique matrix signature. J Thorac Cardiovasc Surg (2011) 1.06
Pressure overload-dependent membrane type 1-matrix metalloproteinase induction: relationship to LV remodeling and fibrosis. Am J Physiol Heart Circ Physiol (2012) 1.06
Matrix modulation and heart failure: new concepts question old beliefs. Curr Opin Cardiol (2005) 1.05
Targeted imaging of the spatial and temporal variation of matrix metalloproteinase activity in a porcine model of postinfarct remodeling: relationship to myocardial dysfunction. Circ Cardiovasc Imaging (2011) 1.04
Differential effects of mechanical and biological stimuli on matrix metalloproteinase promoter activation in the thoracic aorta. Circulation (2009) 1.03
Endothelin-A receptor inhibition after cardiopulmonary bypass: cytokines and receptor activation. Ann Thorac Surg (2008) 1.03
Selective induction of matrix metalloproteinases and tissue inhibitor of metalloproteinases in atrial and ventricular myocardium in patients with atrial fibrillation. Am J Cardiol (2006) 1.02
Effect of increased pressure loading on heart growth in neonatal rats. J Mol Cell Cardiol (2003) 1.02
Confocal imaging of the embryonic heart: how deep? Microsc Microanal (2005) 1.02
Plasma matrix metalloproteinase and inhibitor profiles in patients with heart failure. J Card Fail (2002) 1.01
Spatiotemporal expression and localization of matrix metalloproteinas-9 in a murine model of thoracic aortic aneurysm. J Vasc Surg (2006) 1.01
Epithelial to mesenchymal transition: the doorway to metastasis in human lung cancers. J Thorac Cardiovasc Surg (2010) 1.00
Membrane-type-1 matrix metalloproteinase transcription and translation in myocardial fibroblasts from patients with normal left ventricular function and from patients with cardiomyopathy. Am J Physiol Cell Physiol (2007) 1.00
Selective matrix metalloproteinase inhibition with developing heart failure: effects on left ventricular function and structure. Circ Res (2003) 1.00
Viscoelastic properties of pressure overload hypertrophied myocardium: effect of serine protease treatment. Am J Physiol Heart Circ Physiol (2002) 1.00
Plasma matrix metalloproteinase-9 level is correlated with left ventricular volumes and ejection fraction in patients with heart failure. J Card Fail (2006) 0.99
Alterations in aortic cellular constituents during thoracic aortic aneurysm development: myofibroblast-mediated vascular remodeling. Am J Pathol (2009) 0.98